Accelerate Diagnostics hopes to raise $45 million through a rights offering, which it would use to support its business strategy and product sales. The company is the maker of the BACcel tool for single-cell microbiology evaluation, which it aims to develop for use in identifying pathogens linked to hospital-acquired infections.

Related Summaries